Esperion Therapeutics Anticipates Positive News For Two Of Its Drug Candidates
Esperion Therapeutics (ESPR) is on the verge of a major catalyst as the company awaits the FDA decision for bempedoic acid as a treatment for increased LDL cholesterol. The agency is scheduled to deliver its verdict on February 21, 2020. The drug is also awaiting the FDA's decision for its use in conjunction with ezetimibe. The latter combination will receive the FDA verdict on February 26, 2020. Both the treatments are aimed at controlling LDL-C while in the combination therapy, the acid